The report segments the market on the basis of product, application, and region. Among various product types, the recombinant nonglycosylated protein segment is expected to account for the largest share of the market in 2015.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
The report “Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin,
Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon,
Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020” analyzes and
studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-
Pacific, and the Rest of the world (RoW).
The global biosimilars market is expected to reach $6.22 Billion by 2020 from $2.29 Billion in 2015, at a
CAGR of 22.1% from 2015 to 2020.
The report segments the market on the basis of product, application, and region. Among various product
types, the recombinant nonglycosylated protein segment is expected to account for the largest share of
the market in 2015. However, the recombinant glycosylated protein segment is expected to grow at the
highest CAGR during the forecast period.
A number of factors such as growing pressure to curtail healthcare expenditure, growing demand of
biosimilar drugs due to their cost effectiveness, rising incidences of various diseases, increasing number
of off-patented drugs, positive outcome in the ongoing clinical trials, and rising demand for biosimilars in
different therapeutic applications such as rheumatoid arthritis and blood disorders are propelling the
growth of the global market. On the other hand, high manufacturing complexities and costs, stringent
regulatory requirements in countries, and innovative strategies by biologic drug manufacturers to restrict
entry of new players are restricting the growth of the global market.
Geographically, the global biosimilars market is dominated by Europe, followed by Asia-Pacific, Rest of
the World (RoW), and North America. However, the Asia-Pacific region is likely to witness the highest
growth rate during the forecast period. Factors such as developing healthcare infrastructure, presence of
a large patient population, increasing funding/investments for the development of biosimilars, and growing
focus of both international and domestic players on emerging Asia-Pacific countries are stimulating the
growth of the market in this region.
The key players in the global market include Sandoz International GmbH (Germany), Hospira, Inc. (U.S.),
Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories (India), Biocon Limited (India),
Mylan, Inc. (U.S.), Amgen (U.S.), Celltrion Inc. (South Korea), Roche Diagnostics (Switzerland), and
Merck KGaA (Germany).
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium
market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in
a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in
consulting assignments and business research across high growth markets, cutting edge technologies
and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global
high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive
collaboration with the clients to identify new opportunities, identify most important customers, write
"Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000
markets and entire value chains for deeper understanding of the unmet insights along with market sizing
and forecasts of niche markets. The new included chapters on Methodology and Benchmarking
presented with high quality analytical infographics in our reports gives complete visibility of how the
numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our
huge market intelligence repository.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Telephone No : 1-888-600-6441